1. Home
  2. NVG vs SRPT Comparison

NVG vs SRPT Comparison

Compare NVG & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NVG
  • SRPT
  • Stock Information
  • Founded
  • NVG 1999
  • SRPT 1980
  • Country
  • NVG United States
  • SRPT United States
  • Employees
  • NVG N/A
  • SRPT N/A
  • Industry
  • NVG Investment Managers
  • SRPT Biotechnology: Pharmaceutical Preparations
  • Sector
  • NVG Finance
  • SRPT Health Care
  • Exchange
  • NVG Nasdaq
  • SRPT Nasdaq
  • Market Cap
  • NVG N/A
  • SRPT N/A
  • IPO Year
  • NVG N/A
  • SRPT 1997
  • Fundamental
  • Price
  • NVG $12.05
  • SRPT $36.27
  • Analyst Decision
  • NVG
  • SRPT Buy
  • Analyst Count
  • NVG 0
  • SRPT 23
  • Target Price
  • NVG N/A
  • SRPT $131.09
  • AVG Volume (30 Days)
  • NVG 568.8K
  • SRPT 4.0M
  • Earning Date
  • NVG 01-01-0001
  • SRPT 05-06-2025
  • Dividend Yield
  • NVG 4.65%
  • SRPT N/A
  • EPS Growth
  • NVG N/A
  • SRPT N/A
  • EPS
  • NVG N/A
  • SRPT N/A
  • Revenue
  • NVG N/A
  • SRPT $2,233,371,000.00
  • Revenue This Year
  • NVG N/A
  • SRPT $64.51
  • Revenue Next Year
  • NVG N/A
  • SRPT $22.40
  • P/E Ratio
  • NVG N/A
  • SRPT N/A
  • Revenue Growth
  • NVG N/A
  • SRPT 59.15
  • 52 Week Low
  • NVG $9.68
  • SRPT $35.46
  • 52 Week High
  • NVG $12.21
  • SRPT $173.25
  • Technical
  • Relative Strength Index (RSI)
  • NVG 56.04
  • SRPT 22.68
  • Support Level
  • NVG $11.73
  • SRPT $35.46
  • Resistance Level
  • NVG $12.12
  • SRPT $64.80
  • Average True Range (ATR)
  • NVG 0.13
  • SRPT 3.78
  • MACD
  • NVG 0.06
  • SRPT -1.64
  • Stochastic Oscillator
  • NVG 90.41
  • SRPT 2.76

About SRPT Sarepta Therapeutics Inc. (DE)

Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.

Share on Social Networks: